Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $21.7 million versus the consensus estimate of $21.24 million.

GUIDANCE:

Corcept Therapeutics sees Q4 2016 revenue of $79-82 million, versus the consensus of $80.3 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.